

Theme	Outcome	R1 - Panel SuRa		R2 - Panel GaNu		R2 - Panel Pa		R2 - Overall		R2 results
		<i>importance</i>		<i>importance</i>		<i>importance</i>		<i>importance</i>		Domain retained
		High (%)	Low (%)	High (%)	Low (%)	High (%)	Low (%)	High (%)	Low (%)	
2	Development of a new fistula	98	0	100	0	98	0	98	0	yes
2	Faecal diversion or proctectomy	98	0	100	0	100	0	97	0	yes
6	Death	98	2	100	0	96	2	97	1	yes
2	Perianal related hospitalisation	96	0	98	0	98	0	97	0	yes
2	Incontinence to solid stool	98	0	98	0	98	2	97	1	yes
2	Recurrence of fistula	100	0	98	0	91	0	96	0	yes
2	Perianal abscess on clinical assessment after intervention	94	0	94	0	100	0	95	0	yes
2	Incontinence to liquid stool	91	0	98	0	98	2	94	1	yes
6	Medical complications specific to the immunosuppression (e.g. opportunistic infections, cancers)	92	0	98	0	92	2	94	1	yes
2	Surgical re-intervention	94	0	96	0	89	2	93	1	yes
3	Unable attend school/work	94	0	94	0	87	7	91	2	yes
2	Pads for continence/leakage	86	0	96	0	96	0	91	0	yes
6	Safety (adverse events) and toxicity	98	0	90	0	88	2	91	1	yes
3	Lifestyle alterations (pain/restriction of activities)	91	0	88	0	91	0	89	0	yes

6	Neurological complications	86	2	88	0	96	2	89	1	yes
7	Duration of healing/improvement	86	0	92	0	87	2	88	1	yes
4	Abscess on MRI following treatment	85	4	96	0	74	2	85	2	yes
4	Fistula response on MRI imaging	78	10	94	0	83	0	85	3	yes
3	Social interaction avoidance	75	2	86	0	98	2	85	1	yes
3	Restriction of sexual activity	72	2	92	0	91	4	85	2	yes
2	Anal pain	76	0	88	2	92	2	85	1	yes
6	Cardio-respiratory complications	83	2	79	0	96	2	85	1	yes
2	Patient-reported reduction in fistula drainage	76	0	84	0	89	2	82	1	yes
3	Modifying how you walk, sit or stand because of your fistula	76	2	78	0	91	4	81	2	yes
3	Embarrassment & feeling isolated	73	2	88	0	77	4	79	2	yes
3	Limitation to moderate activities	79	0	76	0	84	0	79	0	yes
2	Complete fistula healing assessed clinically	79	4	92	2	66	4	78	3	yes
3	Feeling depressed & down and hopelessness	68	4	82	0	87	9	78	4	yes
6	Allergic reaction	76	0	80	0	82	2	78	1	yes

3	Change in general health - psychological	73	2	80	0	83	2	78	1	yes
3	Avoidance of intimacy	71	0	84	0	78	2	77	1	yes
3	Anxiety & worries	71	6	69	0	93	0	77	2	yes
3	Change in lifestyle based on toileting needs	72	2	77	0	83	4	77	2	yes
2	Discrimination between passing stool and gas	62	2	76	0	90	2	75	1	yes
3	Physically restricted in self care	67	0	82	0	78	7	74	2	yes
4	MRI assessment of fistula volume	49	20	80	2	89	4	71	9	yes
3	Change in general health - physical	53	2	69	2	92	0	71	1	yes
2	§ Reversal of defunctioning stoma	82	2	70	5	76	9	71	5	yes
2	#§ Need to access medical care	51	7	67	3	93	2	69	4	yes
2	#Wound infection	30	0	81	2	96	0	68	1	yes
3	Concerns about and impact on fertility, birth, parenthood and family	51	2	83	0	79	5	68	2	no
3	Sleep disturbance	54	6	68	4	85	2	68	4	no
4	#Hyperintensity on T2 weighted MRI	67	6	63	0	98	0	67	2	yes
3	§ Patient global satisfaction with management and outcome	63	0	79	4	67	10	67	4	no

3	Tolerability of treatment	60	0	65	2	78	0	67	1	no
2	Faecal urgency	44	2	70	0	88	4	66	2	no
7	Period of time off biologics/anti-TNFs/immunosuppression	75	0	58	8	67	10	65	6	no
6	Surgical complications specific to the surgical procedure (e.g. plug extrusion)	56	4	72	0	81	2	64	2	no
3	A feeling of being unhygienic	42	8	64	4	89	4	64	5	no
2	Rectal mucosal healing	65	2	77	2	47	13	62	6	no
6	#Urinary complications	33	0	58	2	98	2	62	1	yes
2	#Development of perianal features of Crohn's (other than fistula)	52	8	46	4	92	0	62	4	yes
3	#Lethargy and fatigue	33	4	60	4	96	0	62	3	yes
3	Modifying travel	48	4	61	0	78	4	61	3	no
2	Mucus leakage	34	2	76	2	77	0	61	1	no
2	Plug for continence/leakage	40	2	63	2	86	2	60	2	no
2	Closure of internal opening	56	14	48	10	80	4	60	9	no
2	Local perianal inflammation/induration assessed clinically	35	4	61	0	85	2	59	2	no
5	Time to loss of response to medical treatments	22	4	75	0	86	0	59	1	no

5	Fever	32	12	71	4	76	2	59	6	no
2	Clinical assessment of drainage either spontaneously or on gentle finger pressure	17	4	68	6	87	2	56	4	no
5	§ Non-inflammatory blood markers for therapeutic drug monitoring (biologics- efficacy)	28	14	60	11	84	0	55	7	no
2	§ Need for ongoing seton	40	14	49	5	82	8	54	9	no
3	*A global assessment of quality of life	42	6	54	6	70	6	54	6	yes
7	Financial implications	42	2	39	0	83	6	54	3	no
4	#Fistula T1 enhancement on MRI	20	10	71	2	91	0	54	4	yes
6	Grading system for surgical complications e.g. Clavien-Dindo	50	9	45	11	83	10	53	9	no
2	*A validated score to assess perianal disease activity e.g. Perianal disease activity index (PDAI)	21	23	59	2	79	6	52	10	yes
7	Recovery time after intervention	30	2	47	2	79	8	51	4	no
4	*An activity based MRI score e.g. Van Assche Score	10	24	67	6	83	0	51	10	yes
2	≥50% tracts not draining on clinical examination	18	16	48	8	87	0	50	8	no
3	Restricted clothing choices	29	4	42	8	81	2	49	5	no
2	*A global assessment of incontinence that covers all aspects of leakage	19	15	69	4	60	7	48	8	yes
4	MRI assessment of rectum (proctitis)	22	32	37	12	85	0	47	14	no

3	Irritable, frustrated and angry	20	16	42	8	83	4	47	9	<i>no</i>
2	#Anal bleeding	8	16	32	4	94	0	44	7	<i>yes</i>
3	Concern over further intervention	24	6	35	4	71	6	42	5	<i>no</i>
2	Partial fistula healing assessed clinically	18	9	33	0	76	2	42	4	<i>no</i>
4	Fistula response on endoanal Ultrasound	2	55	44	13	69	16	35	27	<i>no</i>

THEME KEY

- 1 Fistula response to treatment (symptoms)
- 2 Direct impact of fistula on the patient
- 3 Impact on the patient as a person
- 4 Assessment with imaging techniques (scans)
- 5 Fistula response to treatment (tests)
- 6 Safety implications related to treatment
- 7 Impact on patient over time

§ De novo outcomes added after round one

*Outcomes which did not meet consensus but were retained by SMG

Retained due to a high patients scoring (≥90%)

Supplementary file 3. Round 2 voting